SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a significant earnings beat and a double-digit revenue jump that defied recent bearish sentiment, fueling active community debates over the sustainability of its AI-driven turnaround. Investors are closely monitoring the company's aggressive capital expenditure plans and the lack of named foundry customers, which have sparked both bullish excitement about long-term potential and skepticism from those concerned about potential future dilution.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as the community closely monitors a potential European regulatory milestone for its flagship drug, MIPLYFFA, following the recent addition of a patent extension to 2041. Investors are actively debating the timing and likelihood of a positive EMA opinion while reacting to a flurry of recent analyst price target upgrades and high institutional interest.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending as investors react to an FDA advisory panel's positive vote on the compounding of several peptides, viewed as a catalyst for potential market expansion. While some in the community highlight the stock's significant short interest and long-term potential, others are actively debating whether the regulatory news is a "buy the rumor, sell the news" event or a fundamental shift in the company's healthcare platform.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is under intense market scrutiny as investors await critical Phase 3 durability data and progress on its rolling NDA submission, which investors view as the final major hurdles before a potential FDA approval for its treatment-resistant depression therapy. The community remains highly active in debating the company's valuation relative to its sector peers, with many bullishly highlighting its first-mover advantage and robust cash position while navigating skepticism and volatility driven by broader macro concerns.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is trending as investors react to a strong quarterly beat and raised guidance, fueling community debate over whether the stock is finally breaking out of its range or if the rally is a temporary "buy the rumor, sell the news" event. Traders are actively discussing the impact of the company's aggressive share buyback program and whether HOKA's continued growth can offset concerns regarding broader retail sector pressures and shifting analyst sentiment.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA approval of Auvelity for the treatment of agitation associated with Alzheimer’s disease, a milestone that community members view as a significant de-risking event and a major growth catalyst. Investors are actively discussing the expanded peak sales potential and the clean label status of the drug, which many believe positions the company as a prime target for future acquisition or long-term value creation.

Albertsons Cos., Inc. engages in the operation of food and drug retail stores. It offers grocery products, general merchandise, health and beauty care products, pharmacy, fuel, and other items and services. The company was founded by Joe Albertson on July 21, 1939 and is headquartered in Boise, ID.

Albertsons Companies Inc - Ordinary Shares - Class A

Albertsons is experiencing significant volatility driven by a major earnings miss and a sharp reduction in full-year guidance, which has left investors debating whether the stock is a distressed value play or facing long-term structural decline. The community is actively discussing signs of capitulation, the impact of competitive pressure from discount grocers, and speculative hope that the company could become an attractive acquisition target despite its current challenges.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing extreme volatility as investors react to management's aggressive AI and robotics spending plans, leading to intense debate among community members over whether this represents a long-term buying opportunity or the end of the stock's growth narrative. The discourse is heavily fueled by technical traders monitoring critical support levels for a potential bounce, while bears and bulls clash over the viability of Musk's long-term vision versus the company's immediate financial performance.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as traders debate whether massive, unusual trading volume signals institutional accumulation or continued market manipulation. The community is focused on the tension between significant short interest and the company's strategic pivot toward agentic AI orchestration, with many investors closely monitoring key technical levels for a potential breakout.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community anticipates CEO Dr. Angelos Stergiou's upcoming media appearance, which is expected to highlight AI's role in advancing cancer immunotherapy and oncology. Investors are closely monitoring the potential for trial-related updates as the REGAL Phase 3 study nears its final event count, fueling discussions about long-term potential and institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +22.75% and +12.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

Equity

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Pelthos Therapeutics Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.40
Prev Close	$26.47
Open	$26.60
Dividend Yield	0.00%
50-Day Moving Average	$27.05
Beta	0.91
Avg. Volume	21,910.00
PE Ratio	-1.38

52-Week High	$37.50
52-Week Low	$16.50
Market Capitalization	$92M
EPS (Annual)	-$23.04
Price to Book	2.73
Revenue Per Employee	$182,554.35

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTHSPelthos Therapeutics Inc.

Latest PTHS News